A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
Future Oncol
; 18(22): 2413-2424, 2022 Jul.
Article
en En
| MEDLINE
| ID: mdl-35674480
Hepatocellular carcinoma (HCC; liver cancer) is common in Chinese patients. Lenvatinib is a drug approved to treat HCC, and patients with higher bodyweights are given a higher dose than patients with lower bodyweights. This trial in Chinese patients with HCC looked at lenvatinib pharmacokinetics (what the body does to a drug) after one dose and multiple doses, and at lenvatinib's antitumor activity and side effects. Meaningful differences in pharmacokinetics between the higher and lower doses after a single dose or multiple doses of daily lenvatinib were not observed. Lenvatinib partially shrank the tumors of 2 out of 21 patients whose tumors were assessed. The side effects seen matched those from other studies of lenvatinib in HCC and other cancers. ClinicalTrial Registration: NCT02953743 (ClinicalTrials.gov).
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Quinolinas
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
/
Antineoplásicos
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
China